FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Novartis Gains Approval for Sickle Cell Therapy

FDA approves a Novartis BLA for Adakveo (crizanlizumab-tmca) for reducing the frequency of vaso-occlusive crisis in sickle cell disease patients.

Human Drugs

Shionogi Urinary Tract Infection Drug Approved

FDA approves a Shionogi & Co. NDA for Fetroja (cefiderocol), an antibacterial drug for treating patients 18 years of age or older with complicated uri...

Human Drugs

Guidance on Smallpox Drug Development

FDA issues a final guidance entitled Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention.

Human Drugs

FDA Funds Quality Management Research Project

FDA funds a $1.7 million two-year project in which five universities will study quality management in FDA drug manufacturing operation inspections.

Federal Register

Final Guide on Export Certificate Denials

Federal Register notice: FDA makes available a final guidance entitled Process to Request a Review of FDAs Decision Not to Issue Certain Export Certif...

Federal Register

Info Collection on Cardiovascular Outcome Claims Guide

Federal Register notice: FDA sends to OMB an information collection extension for Hypertension Indication: Drug Labeling For Cardiovascular Outcome Cl...

Medical Devices

Ultromics EchoGo Core Heart Scan Checker Cleared

FDA clears an Ultromics 510(k) for its image analysis system EchoGo Core, which uses artificial intelligence to automate the analysis and quantificati...

Federal Register

Info Collection Extension on Device Quality System

Federal Register notice: FDA submits to OMB an information collection extension for Medical Devices: Current Good Manufacturing Practice Quality Syste...

Human Drugs

FDA Warns Dollar Tree on Unsafe OTC Drugs

FDA warns Dollar Tree about its receipt of over-the-counter drugs manufactured by foreign contract firms that have received FDA Warning Letters for ma...

Human Drugs

AstraZeneca/Merck NDA for Neurofibromatosis Drug

FDA accepts for priority review an AstraZeneca and Merck NDA for MEK 1/2 inhibitor selumetinib for pediatric patients with neurofibromatosis type 1 an...